AgomAb Therapeutics N.V. American Depositary Shares Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) holds an ST Score of 66.1 out of 100 (B), with its strongest factor being Financial Strength (A+) and its weakest Growth (D+). AGMB last traded at $11.70.
- Strongest
- Financial StrengthA+
- Weakest
- GrowthD+
All factor grades
- Financial StrengthA+
- ValuationA
- ProfitabilityA
- ForecastA
- MomentumD+
- GrowthD+
Contact
AGMB stock: frequently asked questions
What is AGMB's ST Score?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) has an ST Score of 66.1 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is AGMB a buy, sell, or hold?
Our own ST Score grades it B (66.1/100). This is data, not investment advice — always do your own research.
What is AGMB's valuation grade?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is AGMB's growth grade?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) earns a growth grade of D+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is AGMB's profitability grade?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is AGMB's financial strength grade?
AgomAb Therapeutics N.V. American Depositary Shares (AGMB) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for AGMB?
The average analyst price target for AgomAb Therapeutics N.V. American Depositary Shares (AGMB) is $35.00, which is +2.0% versus the recent price of $11.70.